Brief: Eliem Therapeutics Announces Last Patient Completed Dosing In Phase 2A Study Of ETX-810 In Patients With Lumbosacral Radicular Pain (LSRP)

Climb Bio

27/06/2022 21:40

June 27 (Reuters) - Eliem Therapeutics Inc  ELYM.O :
    * ELIEM THERAPEUTICS ANNOUNCES LAST PATIENT COMPLETED DOSING
IN
PHASE 2A STUDY OF ETX-810 IN PATIENTS WITH LUMBOSACRAL RADICULAR
PAIN (LSRP)
    * ELIEM THERAPEUTICS INC- TOPLINE DATA FROM PHASE 2A
CLINICAL
TRIAL ARE EXPECTED IN Q3 OF 2022

Source text for Eikon:  ID:nGNX1Skmc4 
Further company coverage:  ELYM.O 

 ((Reuters.Briefs@thomsonreuters.com;))